References
- 1. N. Cho, J. Shaw, S. Karuranga, Y. Huang, J. da Rocha Fernandes, A. Ohlrogge and B. Malanda, IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045, Diabetes Res. Clin. Pract. 138 (2018) 271–281; https://doi.org/10.1016/j.diabres.2018.02.02310.1016/j.diabres.2018.02.02329496507
- 2. X. Lin, Y. Xu, X. Pan, J. Xu, Y. Ding, X. Sun, X. Song, Y. Ren and P.-F. Shan, Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025, Sci. Rep. 10 (2020) Article ID 14790; https://doi.org/10.1038/s41598-020-71908-910.1038/s41598-020-71908-9747895732901098
- 3. O. Oguntibeju, Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links, Int. J. Physiol. Pathophysiol. Pharmacol. 11 (2019) 45–63.
- 4. F. G. De Felice and S. T. Ferreira, Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease, Diabetes 63 (2014) 2262–2272; https://doi.org/10.2337/db13-195410.2337/db13-195424931033
- 5. A. B. Goldfine, R. Silver, W. Aldhahi, D. Cai, E. Tatro, J. Lee and S. E. Shoelson, Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes, Clin. Transl. Sci. 1 (2008) 36–43; https://doi.org/10.1111/j.1752-8062.2008.00026.x10.1111/j.1752-8062.2008.00026.x266258719337387
- 6. R. Singh, A. Barden, T. Mori and L. Beilin, Advanced glycation end-products: a review, Diabetologia 44 (2001) 129–146; https://doi.org/10.1007/s00125005159110.1007/s00125005159111270668
- 7. P. Muthenna, C. Akileshwari, M. Saraswat and G. B. Reddy, Inhibition of advanced glycation end-product formation on eye lens protein by rutin, Br. J. Nutr. 107 (2012) 941–949; https://doi.org/10.1017/S000711451100407710.1017/S000711451100407721864418
- 8. K. M. Khan, M. Khan, N. Ambreen, M. Taha, F. Rahim, S. Rasheed, S. Saied, H. Shafi, S. Perveen and M. I. Choudhary, Oxindole derivatives: Synthesis and antiglycation activity, J. Med. Chem. 9 (2013) 681–688; https://doi.org/10.2174/157340641130905000710.2174/157340641130905000723190000
- 9. S. Madsbad, Impact of postprandial glucose control on diabetes-related complications: how is the evidence evolving?, J. Diabetes Complicat. 30 (2016) 374–385; https://doi.org/10.1016/j.jdiacomp.2015.09.01910.1016/j.jdiacomp.2015.09.01926541075
- 10. M. Hanefeld and F. Schaper, The Role of Alpha-glucosidase Inhibitors (Acarbose), in Pharmacotherapy of Diabetes: New Developments (Ed. C. E. Mogensen), Springer, New York 2007, pp. 143–152.10.1007/978-0-387-69737-6_13
- 11. A. Ibrar, S. Zaib, I. Khan, Z. Shafique, A. Saeed and J. Iqbal, New prospects for the development of selective inhibitors of α-glucosidase based on coumarin-iminothiazolidinone hybrids: Synthesis, in-vitro biological screening and molecular docking analysis, J. Taiwan Inst. Chem. E 81 (2017) 119–133; https://doi.org/10.1016/j.jtice.2017.09.04110.1016/j.jtice.2017.09.041
- 12. T. Jazzazi, T. S. Ababneh and E. K. Abboushi, Zinc(II) complexes of symmetrical tetradentate Schiff base ligands derived from 2,2’-diamino-6,6’-dibromo-4,4’-dimethyl-1,1’-biphenyl-salicylaldehyde: Synthesis, characterization and computational study, Jordan J. Chem. 14 (2019) 81–87.
- 13. T. S. Ababneh, M. El-Khateeb, A. K. Tanash, T. M. A. AL-Shboul, M. J. A. Shammout, T. M. A. Jazzazi, M. Alomari, S. Daoud and W. Talib, Synthesis, computational, anticancerous and antiproliferative effects of some copper, manganese and zinc complexes with ligands derived from symmetrical 2,2’-diamino-4,4’-dimethyl-1,1’-biphenyl-salicylaldehyde, Pol. J. Chem. Technol. 23 (2021) 7–15; https://doi.org/10.2478/pjct-2021-000210.2478/pjct-2021-0002
- 14. M. Taha, N. Ismail, S. Imran, M. Rokei, S. M. Saad, K. M. and K. M. Khan, Synthesis of new oxadiazole derivatives as α-glucosidase inhibitors, Bioorg. Med. Chem. 23 (2015) 4155–4162; https://doi.org/10.1016/j.bmc.2015.06.06010.1016/j.bmc.2015.06.06026183542
- 15. S. Rasheed, S. S. Sánchez, S. Yousuf, S. M. Honoré and M. I. Choudhary, Drug repurposing: Invitro anti-glycation properties of 18 common drugs, PLoS One 13 (2018) e0190509; https://doi.org/10.1371/journal.pone.019050910.1371/journal.pone.0190509575406229300762
- 16. S. L. Helfand, J. Werkmeister and J. C. Roder, Chemiluminescence response of human natural killer cells. I. The relationship between target cell binding, chemiluminescence, and cytolysis, J. Exp. Med. 156 (1982) 492–505; https://doi.org/10.1084/jem.156.2.49210.1084/jem.156.2.49221867536178787
- 17. G. Wu, D. H. Robertson, I. Brooks and M. J. Vieth, Detailed analysis of grid-based molecular docking: A case study of CDOCKER–A CHARMm-based MD docking algorithm, J. Comput. Chem. 24 (2003) 1549–1562; https://doi.org/10.1002/jcc.1030610.1002/jcc.1030612925999
- 18. I. Alsalahat, Z. M. Al-Majdoub, M. O. Taha, J. Barber, H. Aojula, N. Hodson and S. Freeman, Inhibition of aggregation of amyloid-β through covalent modification with benzylpenicillin; potential relevance to Alzheimer’s disease, Biochem. Biophys. Rep. 26 (2021) Article ID 100943; https://doi.org/10.1016/j.bbrep.2021.10094310.1016/j.bbrep.2021.100943798569333778168
- 19. F. Ali, K. M. Khan, U. Salar, M. Taha, N. H. Ismail, A. Wadood, M. Riaz and S. Perveen, Hydrazinyl arylthiazole based pyridine scaffolds: Synthesis, structural characterization, in vitro α-glucosidase inhibitory activity, and in silico studies, Eur. J. Med. Chem. 138 (2017) 255–272; https://doi.org/10.1016/j.ejmech.2017.06.04110.1016/j.ejmech.2017.06.04128672278
- 20. M. S. Bodnarchuk, Water, water, everywhere..It’s time to stop and think, Drug Discov. Today 21 (2016) 1139–1146; https://doi.org/10.1016/j.drudis.2016.05.00910.1016/j.drudis.2016.05.00927210724
- 21. R. Pinal, Effect of molecular symmetry on melting temperature and solubility, Org. Biomol. Chem. 2 (2004) 2692–2699; https://doi.org/10.1039/B407105K10.1039/b407105k15351835
- 22. G. Klebe, Applying thermodynamic profiling in lead finding and optimization, Nat. Rev. Drug Discov. 14 (2015) 95–110; https://doi.org/10.1038/nrd448610.1038/nrd448625614222
- 23. D. Cervantes-Laurean, D. D. Schramm, E. L. Jacobson, I. Halaweish, G. G. Bruckner and G. A. Boissonneault, Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites, J. Nutr. Biochem. 17 (2006) 531–540; https://doi.org/10.1016/j.jnutbio.2005.10.00210.1016/j.jnutbio.2005.10.00216443355
- 24. K. M. Khan, M. Khan, M. Ali, M. Taha, S. Rasheed, S. Perveen and M. I. Choudhary, Synthesis of bis-Schiff bases of isatins and their antiglycation activity, Bioorg. Med. Chem. 17 (2009) 7795–7801; https://doi.org/10.1016/j.bmc.2009.09.02810.1016/j.bmc.2009.09.02819837595
- 25. G. Abbas, A. S. Al-Harrasi, H. Hussain, J. Hussain, R. Rashid and M. I. Choudhary, Antiglycation therapy: Discovery of promising antiglycation agents for the management of diabetic complications, Pharm. Biol. 54 (2016) 198–206; https://doi.org/10.3109/13880209.2015.102808010.3109/13880209.2015.102808025853955
- 26. C. Padumadasa, D. Dharmadana, A. Abeysekera and M. Thammitiyagodage, In vitro antioxidant, anti-inflammatory and anticancer activities of ethyl acetate soluble proanthocyanidins of the inflorescence of Cocos nucifera L. BMC Complement. Altern. Med. 16 (2016) Article ID 345 (6 pages); https://doi.org/10.1186/s12906-016-1335-210.1186/s12906-016-1335-2501187927595601